Value Of Molecular Diagnosis Of Thyroid Cancer

Published Sep 17, 2012
Boston, MA, USA– Up to 25% of patients who are tested for thyroid cancer using Fine-Needle Aspiration Biopsy (FNAB) may receive indeterminate diagnostic results. These patients usually go through a diagnostic thyroid surgery in order to determine if their thyroid nodule is cancerous. A new molecular test could potentially reduce indeterminate test results that frequently occur in the diagnosis of thyroid cancer using FNAB. This test would decrease unnecessary surgeries and could be a cost-saving strategy when compared to FNAB, which is currently the standard of practice. The aim of the study, “Cost-effectiveness of Using a Molecular Diagnostic Test to Improve Pre-Operative Diagnosis of Thyroid Cancer" was to estimate the clinical and economic benefit of utilizing a molecular diagnostic test (DX test) that can improve the diagnosis of thyroid cancer. Assuming 95% sensitivity and specificity of the DX test when used as an adjunct to FNAB, utilization of the DX test resulted in a positive gain of quality-adjusted life-years (QALYs) and significant cost-savings per patient. If the cost of the DX test is less than $500 (approximately) per test, we expect to save QALYs and reduce costs when it is utilized. Sensitivity of the DX test, compared to specificity, had a larger influence upon the overall outcomes. Lead Author, Mehdi Najafzadeh, Ph.D, says, “Using this molecular test- that can be developed based on gene or protein expression studies- appears to be a dominant diagnostic strategy. If the new test proves to have high accuracy with a reasonable cost per test, it can reduce unnecessary surgeries. This can increase patients’ quality of life and save cost at the same time.” The full study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now